Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

California Senate weighs Rx PSE

This article was originally published in The Tan Sheet

Executive Summary

The California Senate's Appropriations Committee May 28 approves a bill making it illegal in the state to buy ephedrine- or pseudophedrine-containing products without a prescription. The Consumer Healthcare Products Association initiated an Internet campaign against the bill's passage, warning California consumers they could lose OTC access to antihistamine and decongestant products such as Zyrtec-D, Sudafed and Claritin-D. The trade group notes the state would incur costs from increased health insurance premiums for state employees and could lose $4.5 million in sales tax revenue if ephedrine and PSE products become Rx-only. CHPA argues that existing federal law and electronic logbooks to monitor purchases of methamphetamine precursors have helped decrease the number of illicit meth labs. Oregon so far is the only state to enact a prescription-only law for all PSE drugs (1"The Tan Sheet" Feb. 23, 2009, p. 3)

The California Senate's Appropriations Committee May 28 approves a bill making it illegal in the state to buy ephedrine- or pseudophedrine-containing products without a prescription. The Consumer Healthcare Products Association initiated an Internet campaign against the bill's passage, warning California consumers they could lose OTC access to antihistamine and decongestant products such as Zyrtec-D , Sudafed and Claritin-D . The trade group notes the state would incur costs from increased health insurance premiums for state employees and could lose $4.5 million in sales tax revenue if ephedrine and PSE products become Rx-only. CHPA argues that existing federal law and electronic logbooks to monitor purchases of methamphetamine precursors have helped decrease the number of illicit meth labs. Oregon so far is the only state to enact a prescription-only law for all PSE drugs (1 (Also see "Wyden To Propose Prescription-Only Status For Pseudoephedrine" - Pink Sheet, 23 Feb, 2009.), p. 3).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102985

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel